Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,245 across all filing types
Latest filing 2020-10-14 Regulatory Filings
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming securities dematerialized/rematerialized during the quarter ended September 2020. It is a compliance certificate from a depository participant to the company and stock exchanges. The document is short (1862 characters) and is a regulatory attestation rather than a financial report or announcement of financial results. It does not contain financial statements or detailed financial data. It is primarily a certification letter related to regulatory compliance. According to the rules, such officer certifications or attestation letters should be classified as Regulatory Filings (RNS).
2020-10-14 English
Please find enclosed herewith a certificate received from Universal Capital Securities Private Limited, Registrar and Share Transfer Agent of the Company under Regulation 74(5) of the Securities ....
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2020. It is issued by the Registrar and Share Transfer Agent and confirms dematerialization/rematerialization of securities during the quarter. The document is a regulatory compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements or detailed financial data. The document length is 4765 characters, which is relatively short and focused on certification. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory compliance document and not a full report or announcement of financial results.
2020-10-14 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is an intimation about a forthcoming Board Meeting scheduled for October 21, 2020, where the company will consider and approve unaudited financial results for the quarter and half year ended September 30, 2020. It references regulatory compliance under SEBI regulations and mentions the closure of the trading window for insiders. The document does not contain any financial data or results itself but is a notice of the meeting where such results will be approved. The document length is 3761 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a board meeting and upcoming financial results, not the financial report itself or a detailed management discussion.
2020-10-13 English
BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/10/2020 ,inter alia, to consider and approve Pursuant to Regulation 29 ....
Regulatory Filings Classification · 95% confidence The document is an intimation about a forthcoming Board Meeting scheduled for October 21, 2020, where the company will consider and approve unaudited financial results for the quarter and half year ended September 30, 2020. It references regulatory compliance under SEBI regulations and mentions closure of the trading window for insiders. The document does not contain any financial data or results itself, nor does it include a report or detailed financial statements. It is a notification about a meeting and related procedural information. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit into other specific categories like Interim Report or Earnings Release.
2020-10-13 English
Pursuant to Regulation 39(3) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that Registrar and Share Transfer ....
Regulatory Filings Classification · 95% confidence The document is a notification under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding the loss of share certificate and issuance of duplicate share certificate. It is an official intimation to the stock exchanges and shareholders about a share certificate issue, not a financial report or management discussion. The content is regulatory in nature, related to compliance and shareholder record-keeping, and does not contain financial data or management commentary. The document length is 4364 characters, which is relatively short and focused on a specific regulatory disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-10-08 English
This is with reference to our letter dated September 25, 2020 regarding submission of Proceedings of 35th Annual General Meeting held on Friday, September 25, 2020 through Video Conferencing/Other ...
AGM Information Classification · 95% confidence The document is a letter dated October 8, 2020, from Bliss GVS Pharma Ltd. correcting the proceedings of the 351st Annual General Meeting held on September 25, 2020. It specifically addresses a correction in the number of members present at the AGM. The content is a correction notice related to the AGM proceedings rather than the AGM materials themselves. The document is short (3322 characters) and serves as an announcement or correction related to the AGM, not the full AGM report or presentation. Therefore, it fits best under AGM Information (AGM-R) as it pertains to AGM proceedings and corrections thereof.
2020-10-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.